The a2 Milk Company has flagged material supply chain disruptions that will significantly impact China label infant milk formula availability during the fourth quarter of 2026, primarily in April and May. Despite strong demand across all product categories and regions in the third quarter, temporary in-market product availability issues have emerged at distributors and retailers, creating a significant operational challenge for the company at a critical time.
The supply constraints stem from a confluence of factors that have accumulated throughout the financial year. Low inventory levels at a2MC dating back to previous Synlait manufacturing challenges have been compounded by recent production disruptions. While Synlait production has now returned to target levels, the company faces a substantial backlog of unfilled purchase orders, with reduced capacity to catch up following Synlait’s sale of its North Island assets. This structural constraint limits the company’s ability to rapidly rebuild stock even as demand remains robust.
External pressures are adding further complexity to the supply equation. Freight availability and costs have been indirectly impacted by Middle East conflict, creating variability in sea freight capacity allocation and increasing the expense of air freight needed to accelerate shipments to China. Simultaneously, new cereulide testing standards relevant to ingredient suppliers and infant milk formula manufacturers are extending quality assurance release times, while enhanced customs clearance requirements and testing measures in China are increasing inspection and sampling rates across the industry. These regulatory and logistical headwinds affect the entire sector but particularly constrain a2MC’s near-term product flows.
The company notes that English label infant milk formula products will experience some exposure to these factors but are not expected to be as significantly impacted during the affected period. However, a2 Genesisโข, which represents approximately 6 percent of cross-border e-commerce sales, is currently experiencing near-term product availability issues due to high demand. The company expects this to be addressed shortly with the resumption of production at a2 Pลkeno following completion of planned canning line capital works and maintenance.
Despite these near-term challenges, the company’s medium-term outlook appears constructive. The supply chain transformation programme at a2 Pลkeno remains on track, with capital upgrade works, recruitment, capability building, product trials, and the China label registration amendment process all progressing as planned. The company expects a ramp up in production during the first half of 2027, suggesting these current disruptions may be temporary in nature rather than structural.
Investors should monitor how quickly a2MC resolves these supply chain issues and whether the disruptions materially impact revenue or market share during the fourth quarter. The company’s ability to maintain customer relationships and brand momentum through this period, particularly given the strength of competitor product recalls supporting a2 demand, will be critical. Updates on Synlait’s order backlog reduction and a2 Pลkeno’s production ramp in the coming quarters will signal whether management’s forecast production recovery is achievable. This announcement has been flagged as price sensitive and material by the ASX.
View the full ASX announcement (PDF)
About The a2 Milk Company Limited (ASX: A2M)
The a2 Milk Company Limited is a dairy nutritionals company that sells A2-type protein branded milk and related products, including infant milk formula and other dairy products. The company operates across Australia, New Zealand, China, rest of Asia, and the United States, manufacturing and selling nutritional products and providing licensing services under the a2 Milk and a2 Platinum brands.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
